687 Enhancement of anti-tumor immunity by ICT01: a novel g9d2 T cell-activating antibody targeting butyrophilin-3A (BTN3A)
Main Authors: | Jennifer Sims, Patrick Brune, René Hoet, Emmanuel Valentin, LE Suong, Sophie Agaugué, Remy Castellano, Alem Truneh |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
442 ICT01, an anti-BTN3A mAb that activates Vg9Vd2 T cells, plus interleukin-2: a potent and promising combination for cancer immunotherapy
by: Jennifer Sims, et al.
Published: (2020-11-01) -
3 Butyrophilin-3a is expressed in multiple solid tumors: translational research supporting the EVICTION study with ICT01, an anti-BTN3A mAb activating Vg9Vd2 T-Cells
by: Clement Ghigo, et al.
Published: (2020-11-01) -
T lymphocyte inhibition by the butyrophilin molecule BTN2A2
by: Ammann, Johannes Ulrich
Published: (2011) -
Allelic diversity of butyrophilin (BTN1A1) gene in Indian bovines
by: Manoj Kumar, et al.
Published: (2018-02-01) -
Immunologische Kreuzreaktivität zwischen dem Myelin-Oligodendrozyten-Glykoprotein (MOG) und Butyrophilin (BTN) bei Multipler Sklerose
by: Guggenmos, Johannes
Published: (2003)